Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Transgene SA
TNGTransgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS. Address: 400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405
Analytics
Objectif de Cours de WallStreet
2.75 EURRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés TNG
Analyse des dividendes TNG
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes TNG
Valorisation des titres TNG
financières TNG
Résultats | 2019 | Dynamique |